GUIP1: a R package for dose escalation strategies in phase I cancer clinical trials
Abstract Background The main objective of phase I cancer clinical trials is to identify the maximum tolerated dose, usually defined as the highest dose associated with an acceptable level of severe toxicity during the first cycle of treatment. Several dose-escalation designs based on mathematical mo...
Main Authors: | D. Dinart, J. Fraisse, D. Tosi, A. Mauguen, C. Touraine, S. Gourgou, M. C. Le Deley, C. Bellera, C. Mollevi |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-06-01
|
Series: | BMC Medical Informatics and Decision Making |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12911-020-01149-3 |
Similar Items
-
Optimal biological dose: a systematic review in cancer phase I clinical trials
by: J. Fraisse, et al.
Published: (2021-01-01) -
What does a modified-Fibonacci dose-escalation actually correspond to?
by: Penel Nicolas, et al.
Published: (2012-07-01) -
Radiation dose escalation in stage III non-small-cell lung cancer.
by: William Thomas Sause, et al.
Published: (2011-11-01) -
Radiation dose escalation for loco-regional recurrence of breast cancer after mastectomy
by: Skinner Heath D, et al.
Published: (2013-01-01) -
Real-world dose escalation of biologics for moderate-to-severe psoriasis in the United States
by: Jashin J. Wu, et al.
Published: (2023-12-01)